Dyadic to Present at The BIO CEO & Investor Conference Monday, February 12, 2007, At 11:45 A.M. EST

Business Wire, Feb 9, 2007

Webcast Will Be Available At www.dyadic.com

JUPITER, Fla. -- Dyadic International, Inc. (Amex:DIL), a global biotechnology company, announced today that CEO Mark Emalfarb will make a presentation to investors at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City, on Monday, February 12, 2007, at 11:45 a.m. EST.

A live webcast of the presentation will be available at www.dyadic.com. The webcast will be available for replay for 30 days.

About Dyadic

Dyadic International, Inc. is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic is applying its technologies to produce enzymes for use in converting various agricultural products (e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable sugars, which can then be used in the production of traditional and cellulosic ethanol as well as other products currently derived from petroleum. Dyadic's C1 technology also is being developed to facilitate the discovery, development and large-scale production of human antibodies and other high-value therapeutic proteins. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries for the textile, pulp & paper and animal feed industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005, and our subsequent filings with the SEC. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.